{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:01:45Z","timestamp":1790863305940,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Derived from our original nomogram study by using the risk variables from multivariable analyses in the derivation cohort of 1383 patients with extranodal NK\/T-cell lymphoma, nasal-type (ENKTCL) who were mostly treated with anthracycline-based chemotherapy, we propose an easily used nomogram-revised risk index (NRI), validated it and compared with Ann Arbor staging, the International Prognostic Index (IPI), Korean Prognostic Index (KPI), and prognostic index of natural killer lymphoma (PINK) for overall survival (OS) prediction by examining calibration, discrimination, and decision curve analysis in a validation cohort of 1582 patients primarily treated with non-anthracycline-based chemotherapy. The calibration of the NRI showed satisfactory for predicting 3- and 5-year OS in the validation cohort. The Harrell\u2019s C-index and integrated Brier score (IBS) of the NRI for OS prediction demonstrated a better performance than that of the Ann Arbor staging system, IPI, KPI, and PINK. Decision curve analysis of the NRI also showed a superior outcome. The NRI is a promising tool for stratifying patients with ENKTCL into risk groups for designing clinical trials and for selecting appropriate individualized treatment.<\/jats:p>","DOI":"10.1038\/s41375-020-0791-3","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T13:03:07Z","timestamp":1583758987000},"page":"130-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making"],"prefix":"10.1038","volume":"35","author":[{"given":"Si-Ye","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Nan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Lin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Quan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ying","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Zhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Min","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9062","authenticated-orcid":false,"given":"Li-Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"791_CR1","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","volume":"113","author":"WY Au","year":"2009","unstructured":"Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113:3931\u20137.","journal-title":"Blood"},{"key":"791_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ijrobp.2013.12.005","volume":"88","author":"QF Liu","year":"2014","unstructured":"Liu QF, Wang WH, Wang SL, Liu YP, Huang WT, Lu N, et al. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer\/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2014;88:806\u201313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"791_CR3","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-08-2914","volume":"15","author":"YX Li","year":"2009","unstructured":"Li YX, Liu QF, Fang H, Qi SN, Wang H, Wang WH, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer\/T-cell lymphoma. Clin Cancer Res. 2009;15:2905\u201312.","journal-title":"Clin Cancer Res"},{"key":"791_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/annonc\/mdn147","volume":"19","author":"TM Kim","year":"2008","unstructured":"Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, et al. Clinical heterogeneity of extranodal NK\/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol. 2008;19:1477\u201384.","journal-title":"Ann Oncol"},{"key":"791_CR5","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1182\/blood-2008-05-160176","volume":"112","author":"YX Li","year":"2008","unstructured":"Li YX, Fang H, Liu QF, Lu J, Qi SN, Wang H, et al. Clinical features and treatment outcome of nasal-type NK\/T-cell lymphoma of Waldeyer ring. Blood. 2008;112:3057\u201364.","journal-title":"Blood"},{"key":"791_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138:429\u201334.","journal-title":"Am J Clin Pathol"},{"key":"791_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","volume":"24","author":"YX Li","year":"2006","unstructured":"Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. J Clin Oncol. 2006;24:181\u20139.","journal-title":"J Clin Oncol"},{"key":"791_CR8","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","volume":"126","author":"Y Yang","year":"2015","unstructured":"Yang Y, Zhu Y, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126:1424\u201332.","journal-title":"Blood"},{"key":"791_CR9","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120:2973\u201380.","journal-title":"Blood"},{"key":"791_CR10","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1080\/10428194.2016.1180689","volume":"57","author":"S Qi","year":"2016","unstructured":"Qi S, Yahalom J, Hsu M, Chelius M, Lunning M, Moskowitz A, et al. Encouraging experience in the treatment of nasal type extra-nodal NK\/T-cell lymphoma in a non-Asian population. Leuk Lymphoma. 2016;57:2575\u201383.","journal-title":"Leuk Lymphoma"},{"key":"791_CR11","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1002\/cncr.30697","volume":"123","author":"JA Vargo","year":"2017","unstructured":"Vargo JA, Patel A, Glaser SM, Balasubramani GK, Farah RJ, Marks SM, et al. The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States. Cancer. 2017;123:3176\u201385.","journal-title":"Cancer"},{"key":"791_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","volume":"35","author":"M Yamaguchi","year":"2017","unstructured":"Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T, et al. Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017;35:32\u201339.","journal-title":"J Clin Oncol"},{"key":"791_CR13","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1182\/bloodadvances.2018021311","volume":"2","author":"T Wu","year":"2018","unstructured":"Wu T, Yang Y, Zhu SY, Shi M, Su H, Wang Y, et al. Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Adv. 2018;2:2369\u201377.","journal-title":"Blood Adv"},{"key":"791_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.radonc.2018.04.026","volume":"129","author":"XW Deng","year":"2018","unstructured":"Deng XW, Wu JX, Wu T, Zhu SY, Shi M, Su H, et al. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK\/T-cell lymphoma: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Radiother Oncol. 2018;129:3\u20139.","journal-title":"Radiother Oncol"},{"key":"791_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","volume":"17","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:389\u2013400.","journal-title":"Lancet Oncol"},{"key":"791_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P.","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl J Med. 1993;329:987\u201394.","journal-title":"N. Engl J Med"},{"key":"791_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837\u201342.","journal-title":"Blood"},{"key":"791_CR18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","volume":"24","author":"J Lee","year":"2006","unstructured":"Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612\u20138.","journal-title":"J Clin Oncol"},{"key":"791_CR19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/leu.2015.44","volume":"29","author":"Y Yang","year":"2015","unstructured":"Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK\/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015;29:1571\u20137.","journal-title":"Leukemia"},{"key":"791_CR20","doi-asserted-by":"publisher","first-page":"E122","DOI":"10.1002\/ajh.25426","volume":"94","author":"H Hong","year":"2019","unstructured":"Hong H, Huang H, Fang X, Wang Z, Ye S, Zhang H, et al. A prognostic index for nasal-type early-stage extranodal natural killer\/T-cell lymphoma: a multicenter study. Am J Hematol. 2019;94:E122\u2013E124.","journal-title":"Am J Hematol"},{"key":"791_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/annonc\/mdx684","volume":"29","author":"YL Kwong","year":"2018","unstructured":"Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, et al. Sequential chemotherapy\/radiotherapy was comparable with concurrent chemoradiotherapy for stage I\/II NK\/T-cell lymphoma. Ann Oncol. 2018;29:256\u201363.","journal-title":"Ann Oncol"},{"key":"791_CR22","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1080\/10428194.2019.1602265","volume":"60","author":"SN Qi","year":"2019","unstructured":"Qi SN, Xu LM, Yuan ZY, Wu T, Zhu SY, Shi M, et al. Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Leuk Lymphoma. 2019;60:2669\u201378.","journal-title":"Leuk Lymphoma"},{"key":"791_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-33","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33.","journal-title":"BMC Med Res Methodol"},{"key":"791_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1198\/016214507000000149","volume":"102","author":"H Uno","year":"2007","unstructured":"Uno H, Cai T, Tian L, Wei L. Evaluating prediction rules for t-years survivors with censored regression models. J Am Stat Assoc. 2007;102:527\u201337.","journal-title":"J Am Stat Assoc"},{"key":"791_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361\u201387.","journal-title":"Stat Med"},{"key":"791_CR26","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/(SICI)1097-0258(19990915\/30)18:17\/18<2529::AID-SIM274>3.0.CO;2-5","volume":"18","author":"E Graf","year":"1999","unstructured":"Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med. 1999;18:2529\u201345.","journal-title":"Stat Med"},{"key":"791_CR27","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2015.65.5654","volume":"34","author":"KF Kerr","year":"2016","unstructured":"Kerr KF, Brown MD, Zhu K, Janes H. Assessing the clinical impact of risk prediction models with decision curves: Guidance for correct interpretation and appropriate use. J Clin Oncol. 2016;34:2534\u201340.","journal-title":"J Clin Oncol"},{"key":"791_CR28","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474\u20139.","journal-title":"Blood"},{"key":"791_CR29","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"791_CR30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"791_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijrobp.2016.09.013","volume":"97","author":"RY Wu","year":"2017","unstructured":"Wu RY, Liu K, Wang WH, Jin J, Song YW, Wang SL, et al. Patterns of primary tumor invasion and regional lymph node spread based on magnetic resonance imaging in early-stage nasal NK\/T-cell lymphoma: Implications for clinical target volume definition and prognostic significance. Int J Radiat Oncol Biol Phys. 2017;97:50\u201359.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"791_CR32","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2005-05-2056","volume":"106","author":"TM Kim","year":"2005","unstructured":"Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)\/II(E) extranodal NK\/T-cell lymphoma, nasal type. Blood. 2005;106:3785\u201390.","journal-title":"Blood"},{"key":"791_CR33","first-page":"e190","volume":"2","author":"X Liu","year":"2019","unstructured":"Liu X, Wu T, Zhu SY, Shi M, Su H, Wang Y, et al. Risk-dependent conditional survival and failure hazard after radiotherapy for early-stage extranodal natural killer\/T-cell lymphoma. JAMA Netw Open. 2019;2:e190\u2013194.","journal-title":"JAMA Netw Open"},{"key":"791_CR34","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1002\/cam4.1849","volume":"7","author":"B Chen","year":"2018","unstructured":"Chen B, Zhu SY, Shi M, Su H, Wang Y, He X, et al. Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK\/T-cell lymphoma: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Cancer Med. 2018;7:5952\u201361.","journal-title":"Cancer Med"},{"key":"791_CR35","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00277-015-2336-9","volume":"94","author":"XW Bi","year":"2015","unstructured":"Bi XW, Jiang WQ, Zhang WW, Huang JJ, Xia Y, Wang Y, et al. Treatment outcome of patients with advanced stage natural killer\/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy. Ann Hematol. 2015;94:1175\u201384.","journal-title":"Ann Hematol"},{"key":"791_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamaoncol.2016.5094","volume":"3","author":"Y Yang","year":"2017","unstructured":"Yang Y, Cao JZ, Lan SM, Wu JX, Wu T, Zhu SY, et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer\/T-cell lymphoma. JAMA Oncol. 2017;3:83\u201391.","journal-title":"JAMA Oncol"},{"key":"791_CR37","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood. 2017;129:2437\u201342.","journal-title":"Blood"},{"key":"791_CR38","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47:1061\u20136.","journal-title":"Nat Genet"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0791-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0791-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0791-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:39:54Z","timestamp":1684604394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0791-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0791-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"4 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}